Table 1: Genetic factors implicated in UC causation
Table 2: Truelove and Witts categorization of disease severity and clinical parameters
Table 3: Pediatric Ulcerative Colitis Activity Index
Table 4: Typical Symptoms of UC
Table 5: Risk Factors and Comorbidities for UC and IBD
Table 6: Incidence of UC in the 5EU
Table 7: Prevalence of UC in Italy, Spain, and the UK
Table 8: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of UC
Table 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of UC
Table 10: 7MM, Sources Used to Forecast Undiagnosed Prevalent Cases of UC
Table 11: 7MM, Sources Used to Forecast the Total Prevalent Cases of UC
Table 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of UC by Stage at Diagnosis
Table 13: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Incident/Prevalent Cases of UC by Severity
Table 14: 7MM, Sources of Epidemiological Data used to Forecast Mortality Due to CRC and TMC Among the Diagnosed Prevalent Cases of UC
Table 15: 7MM, Sources Used to Forecast Autoimmune Comorbidities Among the Diagnosed Prevalent Cases of UC
Table 16: 7MM, Sources Used to Forecast UC Cases Requiring Colectomy Among the Diagnosed Prevalent Cases of UC Due to Failure of Medical Management
Table 17: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of IC
Table 18: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IC
Table 19: 7MM, Sources Not Used in Epidemiological Analysis of UC
Table 20: 7MM, Diagnosed Incident Cases of UC, Both Sexes, All Ages, N, Selected Years 2015–2025
Table 21: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, N (Row %), 2015
Table 22: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N (Row %), 2015
Table 23: 7MM, Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, Selected Years, 2015–2025
Table 24: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N (Row %), 2015
Table 25: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N (Row %), 2015
Table 26: 7MM, Undiagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, Select Years, 2015–2025
Table 27: 7MM, Age-Specific Undiagnosed Prevalent Cases of UC, Both Sexes, N (Row %), 2015
Table 28: 7MM, Sex-Specific Undiagnosed Prevalent Cases of UC, All Ages, N (Row %), 2015
Table 29: 7MM, Total Prevalent Cases of UC, Both Sexes, All Ages, N, Selected Years, 2015–2025
Table 30: 7MM, Age-Specific Total Prevalent Cases of UC, Both Sexes, N (Row %), 2015
Table 31: 7MM, Sex-Specific Total Prevalent Cases of UC, All Ages, N (Row %), 2015
Table 32: 7MM, Diagnosed Incident Cases of IC, Both Sexes, All Ages, N, Selected Years, 2015–2025
Table 33: 7MM, Diagnosed Prevalent Cases of IC, Both Sexes, All Ages, N, Selected Years, 2015–2025
Table 34: Diagnostic features of UC
Table 35: Truelove and Witts categorization of disease severity and clinical parameters
Table 36: UCDAI
Table 37: Pediatric Ulcerative Colitis Activity Index
Table 38: Treatment Guidelines for Ulcerative Colitis
Table 39: Most Prescribed Drugs for Ulcerative Colitis by Class in the Global Markets, 2015
Table 40: Different 5-ASAs used for managing UC
Table 41: Different corticosteroids used for managing UC
Table 42: Country Profile – US
Table 43: Region Profile – 5EU
Table 44: Country Profile – Japan
Table 45: Leading Treatments for UC, 2015
Table 46: Product Profile – Lialda
Table 47: Efficacy of different drugs in 5-ASA class in inducing remission in UC patients
Table 48: Efficacy of different drugs in 5-ASA class in preventing disease relapse in UC patients
Table 49: Percentage of patients experiencing adverse events with 5-ASAs
Table 50: 5-ASA SWOT Analysis, 2015
Table 51: Product Profile –Steroids
Table 52: Efficacy of Uceris
Table 53: Safety of Uceris
Table 54: Uceris SWOT Analysis, 2016
Table 55: Product Profile –Azathioprine
Table 56: Percentage of patients experiencing adverse events with AZA and 6-MP therapy
Table 57: Azathioprine SWOT Analysis, 2015
Table 58: Product Profile –MTX
Table 59: MTX SWOT Analysis, 2015
Table 60: Product Profile –Remicade
Table 61: Efficacy data for ACT 1 and ACT 2 trials
Table 62: Safety of Remicade
Table 63: SWOT Analysis, Remicade 2016
Table 64: Product Profile -Humira
Table 65: Efficacy of Humira – Primary and Secondary Endpoints-ULTRA 2 Phase III Program
Table 66: SWOT Analysis, Humira 2016
Table 67: Product Profile -Simponi
Table 68: Efficacy of Simponi
Table 69: Safety of Simponi
Table 70: Simponi SWOT Analysis, 2016
Table 71: Product Profile – Entyvio
Table 72: Efficacy of Entyvio
Table 73: Efficacy of Entyvio
Table 74: Safety of Entyvio
Table 75: Entyvio SWOT Analysis
Table 76: Infliximab Biosimilars for UC Treatment
Table 77: Product Profile –Infliximab biosimilar
Table 78: Percentage of patients experiencing adverse events with infliximab biosimilars
Table 79: Biosimilars SWOT Analysis, 2015
Table 80: Unmet Need and Opportunity in UC, 2015
Table 81: Late stage development drugs for UC, 2015–2025
Table 82: Product Profile – Ustekinumab
Table 83: Ustekinumab SWOT Analysis, 2015
Table 84: Product Profile – Etrolizumab
Table 85: Efficacy of Etrolizumab
Table 86:Safety of Etrolizumab
Table 87 : Pipeline Drug Etrolizumab SWOT Analysis, 2016
Table 88: Product Profile – LT-02
Table 89: Efficacy Analysis for LT-02
Table 90: Efficacy Analysis for Different Doses of LT-02
Table 91: LT-02 SWOT Analysis, 2015
Table 92: Product Profile – Kappaproct
Table 93: Safety of Kappaproct
Table 94: Kappaproct SWOT Analysis, 2016
Table 95: Product Profile – Xeljanz
Table 96: Patient reported outcomes for Xeljanz compared to placebo
Table 97: Mean change from baseline in partial Mayo score in Xeljanz and placebo groups
Table 98: Mean change from baseline in partial Mayo score in Xeljanz and placebo groups
Table 99: Rates of various adverse events experienced in Xeljanz and placebo groups
Table 100: Xeljanz SWOT Analysis, 2015
Table 101: Product Profile – Ozanimod hydrochloride
Table 102: Efficacy analysis of Ozanimod
Table 103: Safety of Ozanimod
Table 104: Pipeline Drug Ozanimod SWOT Analysis, 2015
Table 105: Product Profile – Carotegrast
Table 106: Efficacy analysis in carotegrast and placebo groups
Table 107: Safety analysis of carotegrast
Table 108: Carotegrast SWOT Analysis, 2015
Table 109: Product Profile – Mesalamine (TP-05)
Table 110: Pipeline Drug TP-05 SWOT Analysis, 2016
Table 111: Product Profile – AJG511
Table 112: Efficacy analysis of AJG511
Table 113: Carotegrast SWOT Analysis, 2015
Table 114: Product Profile – Infliximab biosimilars
Table 115: Infliximab biosimilars SWOT Analysis, 2015
Table 116: Product Profile – Amjevita
Table 117: Amjevita SWOT Analysis, 2016
Table 118: Key Companies in the Ulcerative Colitis Market in the 7MM, 2015
Table 119: J&J’s UC Portfolio Assessment, 2015
Table 120: AbbVie’s UC Portfolio Assessment, 2015
Table 121: Takeda’s UC Portfolio Assessment, 2015
Table 122: Salix Pharmaceuticals’ UC Portfolio Assessment, 2015
Table 123: Pfizer’s UC Portfolio Assessment, 2015
Table 124: Roches UC Portfolio Assessment, 2015
Table 125: InDex Pharmaceutical’s UC Portfolio Assessment, 2015
Table 126: Lipid Therapeutics’ UC Portfolio Assessment, 2015
Table 127: Celgene’s UC Portfolio Assessment, 2015
Table 128: EA Pharma’s UC Portfolio Assessment, 2015
Table 129: Ferring Pharmaceuticals’ UC Portfolio Assessment, 2015
Table 130: Tillotts Pharma’s UC Portfolio Assessment, 2015
Table 131:Ulcerative Colitis Market – Global Drivers and Barriers, 2015?2025
Table 132: Key Events Impacting Sales for Ulcerative Colitis in the US, 2015–2025
Table 133: Ulcerative Colitis Market – Drivers and Barriers in the US, 2015?2025
Table 134: Key Events Impacting Sales for Ulcerative Colitis in France, 2015–2025
Table 135: Ulcerative Colitis Market – Drivers and Barriers in France, 2015?2025
Table 136: Key Events Impacting Sales for Ulcerative Colitis in Germany, 2015–2025
Table 137: Ulcerative Colitis Market – Drivers and Barriers in Germany, 2015?2025
Table 138: Key Events Impacting Sales for Ulcerative Colitis in Italy, 2015–2025
Table 139: Ulcerative Colitis Market – Drivers and Barriers in Italy, 2015?2025
Table 140: Key Events Impacting Sales for Ulcerative Colitis in Spain, 2015–2025
Table 141: Ulcerative Colitis Market – Drivers and Barriers in Spain, 2015?2025
Table 142: Key Events Impacting Sales for Ulcerative Colitis in the UK, 2015–2025
Table 143: Ulcerative Colitis Market – Drivers and Barriers in UK, 2015?2025
Table 144: Key Events Impacting Sales for Ulcerative Colitis in Japan, 2015–2025
Table 145: Ulcerative Colitis Market – Drivers and Barriers in Japan, 2015?2025
Table 146: Key Projected Launch Dates for UC
Table 147: Key Historical and Projected Patent Expiry Dates for UC
Table 148: High-Prescribing Physicians (non-KOLs) Surveyed, By Country